



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

January 17, 2024

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
**Mumbai 400 001**

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Please find enclosed herewith the Press Release and disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 which is enclosed as Annexure – I.

This is for your information.

Thanking you,

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

**Ref: PR/09/2023-24**

### **NATCO Pharma Limited invests around US\$ 2 million in Cellogen Therapeutics Private Limited**

Cellogen Therapeutics Private Limited, a Delhi based biotech startup promoted by Dr. Gaurav Kharya, Director, Centre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi has raised around US\$ 2 million from NATCO Pharma Limited. Cellogen is primarily involved in two R&D programs involving cell and gene therapy solutions.

Chimeric Antigen Receptor T (CAR T) cell therapy program is at an advanced stage for Cellogen Therapeutics where the T cells of the patients are genetically engineered to identify and kill the cancer cells. Cellogen Therapeutics has developed bi-specific CARs and also added another co-stimulatory domain to increase the efficacy and persistence of the CAR in human body as compared to currently available CAR constructs that are mono-specific with one co-stimulatory domain. Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy which remains a major challenge with existing CAR constructs. Current available products in market cost around US\$ 500,000 – 700,000 which Cellogen aims to bring down to US\$ 60,000 – 70,000.

Another program on which Cellogen Therapeutics is working is gene therapy program for transfusion dependent thalassemia and sickle cell disease. It is noteworthy that these two diseases form the largest burden of red cell disorders across the globe. As per rough estimates, 40,000 kids are born each year with these disorders in India (10,000 with thalassemia and 30,000 with sickle cell disease).

“Cellogen has been working on its next generation CAR T programme for around 2.5 years and has been able to zero in on one particular CAR construct amongst around 40 such constructs. After successful pre-clinical data using the selected CAR, Cellogen intends to start phase 1 clinical trial in the first half of 2024. Just like the CAR T cell therapy, Cellogen Therapeutics also intends to bring gene therapy solutions at affordable cost to our patients in need,” said Dr. Gaurav Kharya, Founder & Director of Cellogen Therapeutics.



## **Natco Pharma Limited**

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, [www.natcopharma.co.in](http://www.natcopharma.co.in)

Sri Rajeev Nannapaneni, Director & CEO, NATCO Pharma Limited states, "Cellogen's area of research work involving innovative and cost-effective cell and gene therapies for addressing various oncological, hematological and metabolic diseases is in line with our core value of providing advanced healthcare with affordability and is basis of our investment thesis. We are excited about these therapies and pleased to partner with Cellogen Therapeutics."

---

For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



## Natco Pharma Limited

Regd. Off : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

### Annexure- I

#### Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

| Sl. No.  | Particulars  | Details of Investment  |
|----------|--|--|
| <b>A</b> | Name of the target entity, details in brief such as size, turnover etc.  | <b>1) Name of the target entity</b><br><br>Cellogen Therapeutics Private Limited ("Cellogen")<br><br><b>2) Details in brief such as size, turnover etc.</b><br><br>Cellogen is involved in research and development of cellular and gene therapies |
| <b>B</b> | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | No   |
| <b>C</b> | Industry to which the entity being acquired belongs  | Healthcare   |
| <b>D</b> | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)   | To support development of affordable cell and gene therapies in India  |
| <b>E</b> | Brief details of any governmental or regulatory approvals required for the acquisition   | Not applicable   |
| <b>F</b> | Indicative time period for completion of the acquisition;  | December 31, 2024  |
| <b>G</b> | Nature of consideration - whether cash consideration or share swap and details of the same   | Cash consideration of ₹ 15.01 crores across three tranches   |
| <b>H</b> | Cost of acquisition or the price at which the shares are acquired  | ₹ 1,32,612.47 per share  |
| <b>I</b> | Percentage of shareholding / control acquired and / or number of shares acquired   | 5.38% shareholding of Cellogen post three tranches on a fully diluted basis  |



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

| Sl. No. | Particulars  | Details of Investment  |
|---------|--|--|
| J       | brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | <p><b>1. Brief background:</b></p> <p>Cellogen is involved in research and development of cellular and gene therapies</p> <p><b>2. Line of business:</b></p> <p>Healthcare</p> <p><b>3. Date of incorporation:</b></p> <p>08/06/2021</p> <p><b>4. Turnover of last 3 years ending December 31 (in US\$):</b></p> <p>NIL</p> <p><b>5. Country in which the acquired entity has presence:</b></p> <p>India</p> |